PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2020–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Shanghai ranks #42,947 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.

#42,947
of 49,997 US assignees by volume
19th percentile
by Innovation Score (26.2/100)
17.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R42947 · Foreign Corporation #42,947 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 6 grants
  • LOWER-Q #42,947/49,997
  • PHOTO-FINISH Shanghai Microport…
  • CPC-NARROW C12N · 5 areas
  • INNOV-THIN 26.2/100
  • CLAIMS-RICH 17.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2020–2022 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Shanghai Microport EP Medtech Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Shanghai

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Shanghai's Innovation Score is 26.2/100 (19th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Shanghai's grants concentrate

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2022. By volume, Shanghai sits between Shanghai Microport EP Medtech Co., Ltd. and Shei Chung Hsin IND. Co., Ltd..

Shanghai's three-year grant acceleration

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd shows 1 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Shanghai's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Shanghai holds 6 patents at rank #42,824, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Shanghai

By rank, the assignees closest to #42,824 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Shanghai's primary technology class.

Shanghai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 19th percentile higher than 19% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 202020212022 1
USPTO utility patent grants by year · 2020–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 2 33.3%
2021 3 50.0%
2022 1 16.7%

Which technologies does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent most?

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#42,947

of 49,997 tracked assignees

Innovation Score

26.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patent record in context - here's where to go next.

  • Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
  • Ranked #42,947 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd against Shanghai Microport EP Medtech Co., Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 26.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.